Rhythm Pharmaceuticals
Yahoo Finance • 16 days ago
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties to sha... Full story
Yahoo Finance • 17 days ago
Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates
Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The "Oral Obesity Therapies Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Oral Obesity Therapies Market Global Report 2026 provides strategists, marketers, invest... Full story
Yahoo Finance • 24 days ago
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story
Yahoo Finance • last month
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the best biotech stocks on this list. TheFly reported on June 16 that Canaccord analyst Whitney I... Full story
Yahoo Finance • last month
Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the most promising healthcare stocks according to Wall Street analysts. On June 13, Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) shared preliminary results from its ongoing Phase 2 trial o... Full story
Yahoo Finance • last month
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas inclu... Full story
Yahoo Finance • 2 months ago
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- -- Bivamelagon therapy achieved progressive reductions in BMI and hunger measures in patients (N=26) w... Full story
Yahoo Finance • 2 months ago
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- --... Full story
Yahoo Finance • 2 months ago
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story
Yahoo Finance • 3 months ago
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday
Key Points The biotech was in the headlines recently after the FDA approved a new indication for its single commercialized drug. There might be more where that came from with Imcivree.10 stocks we like better than Rhythm Pharmaceuticals ›... Full story
Yahoo Finance • 3 months ago
Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) ranks 5th on this list. While Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) faces high cash burn, hedge fu... Full story
Yahoo Finance • 4 months ago
Rhythm Pharmaceuticals Announces Changes to Board of Directors
-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the l... Full story
Yahoo Finance • 4 months ago
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming... Full story
Yahoo Finance • 4 months ago
Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'
Rhythm Pharmaceuticals stock ultimately closed down Friday, though the FDA signed off on its drug, Imcivree, for a genetic form of obesity. Continue Reading... Full story
Yahoo Finance • 4 months ago
Stocks Fall on Spillover Effects from Iran War
The S&P 500 Index ($SPX) (SPY) today is down -0.88%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.59%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.22%. March E-mini S&P futures (ESM26) are down -0.95%, and March E-mini... Full story
Yahoo Finance • 4 months ago
Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) is one of the most promising stocks under $100 to buy. On March 16, Rhythm Pharmaceuticals announced topline results from its global Phase 3 EMANATE trial, which evaluated the efficacy of setmelano... Full story
Yahoo Finance • 4 months ago
Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'
Rhythm Pharmaceuticals stock popped Friday after the FDA signed off on its obesity drug for patients with a rare, hunger-spiking disease. Continue Reading... Full story
Yahoo Finance • 4 months ago
Rhythm Secures FDA Approval For IMCIVREE In Acquired Hypothalamic Obesity
(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced that the FDA has approved IMCIVREE for the treatment of acquired hypothalamic obesity, marking the first and only therapy cleared for this rare and severe condition. Acquired hypot... Full story
Yahoo Finance • 4 months ago
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction – -- Indicated to reduce excess... Full story
Yahoo Finance • 4 months ago
Rhythm Pharmaceuticals (RYTM) PT Increased From $136 to $143 at Wells Fargo on IMCIVREE Launch Optimism
We recently compiled a list of the Top 10 Boring Stocks That Make Money. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the most boring stocks that make money. TheFly reported on March 12 that Wells Fargo increased its price target... Full story
- WFC